Welcome to our dedicated page for PACS Group SEC filings (Ticker: PACS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The PACS Group, Inc. (NYSE: PACS) SEC filings page on Stock Titan brings together the company’s regulatory disclosures from the U.S. Securities and Exchange Commission, along with AI-powered summaries to help interpret them. As a healthcare holding company in the post-acute care and medical care facilities space, PACS uses SEC reports to describe its facility portfolio, credit arrangements, governance, and risk profile.
Investors can review annual reports on Form 10-K and quarterly reports on Form 10-Q for detailed discussions of PACS Group’s operations, financial condition, and risk factors. These filings also provide context on the company’s role as a holding company, the structure of its independent operating subsidiaries, and the separation between licensed healthcare providers and non-provider entities. AI-generated highlights can point out key sections on post-acute care operations, use of credit facilities, and lease obligations.
Current reports on Form 8-K are particularly important for PACS, given its history of restatements, credit agreement amendments, and NYSE listing updates. Recent 8-K filings have addressed topics such as forbearance and amendments under the company’s amended and restated credit agreement, events of default and related waivers, NYSE listing extensions tied to delayed SEC filings, and the completion of an independent Audit Committee investigation and related restatements. AI summaries can help users quickly understand the implications of these events.
Users can also access proxy materials such as the Definitive Proxy Statement on Schedule 14A, which outlines matters presented to stockholders at the annual meeting, including director elections, auditor ratification, and advisory votes on executive compensation. In addition, the filings page provides real-time updates from EDGAR and convenient access to other forms, such as notifications of late filings on Form 12b-25. Together, these documents offer a comprehensive view of PACS Group’s regulatory history, governance decisions, and financial reporting, with AI tools available to simplify and explain complex disclosures.
PACS filing a Form 144 reporting proposed sales by an insider. The filing lists two sale notices by Mark Hancock totaling 236,320 shares sold on 06/15/2026 ($5,568,759.95) and 06/16/2026 ($2,982,385.05), respectively. The record shows securities originally acquired at formation on 03/01/2023 and an aggregate holding line of 54,626,199 shares as of 03/01/2023. The broker-dealer listed is Citigroup Global Markets Inc on the NYSE.
PACS Group, Inc. director and co-founder Mark Hancock reported open-market sales of company common stock. Across four transactions on June 15–16, 2026, he sold a total of 236,320 shares, including 83,066 shares at a weighted average price of $35.9038 per share and 134,093 shares at $36.2341 per share.
The filing states these sales were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on March 11, 2026, indicating they were scheduled in advance. After these transactions, Hancock directly owned 54,366,277 shares of PACS Group common stock.
Mark Hancock reports a Rule 144 sale of 153,254 shares of Common Stock. The filing records a trade date of 06/15/2026 and proceeds of $5,568,759.95. The notice names Citigroup Global Markets Inc and also shows 54,626,199 shares acquired at formation on 03/01/2023 as background information.
PACS Group, Inc. reported the results of its 2026 Annual Meeting of Stockholders held on June 10, 2026. A total of 152,966,362 shares of common stock were represented online or by proxy, representing approximately 97.33% of shares outstanding as of the April 15, 2026 record date, indicating very high stockholder participation.
Stockholders elected Class II directors Evelyn Dilsaver and Mark Hancock to serve until the 2029 Annual Meeting. Dilsaver received 138,610,797 votes for and 7,339,538 votes withheld, while Hancock received 145,054,309 votes for and 896,026 votes withheld, with 7,016,027 broker non-votes for each nominee.
Stockholders also ratified the appointment of Ernst & Young LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026, with 152,909,016 votes for, 46,759 against, and 10,587 abstaining. In addition, they approved, on an advisory and non-binding basis, the compensation of the company’s named executive officers, with 131,950,911 votes for, 13,973,853 against, 25,571 abstentions, and 7,016,027 broker non-votes.
PACS Group, Inc. director Patrick Hugh Conway received a grant of 4,660 restricted stock units (RSUs) of Common Stock. These RSUs convert into one share each upon vesting, giving him 8,157 shares in total after the award. All RSUs vest 100% on the earlier of June 10, 2027 or the next annual meeting following the grant date, as long as he continues serving the company.
LEAVITT TAYLOR S. reported acquisition or exercise transactions in this Form 4 filing.
PACS Group, Inc. director Taylor S. Leavitt received an equity grant of 4,660 restricted stock units (RSUs), each convertible into one share of common stock upon vesting. After this award, Leavitt holds 15,497 shares of common stock directly.
The RSUs will vest 100% on the earlier of June 10, 2027 or the date of the next annual meeting following the grant, as long as Leavitt continues to serve the company. This filing reflects a compensation-related share award rather than an open-market purchase or sale.
PACS Group, Inc. director Jacqueline Millard reported a stock-based compensation award. She acquired 4,660 shares of Common Stock in the form of restricted stock units (RSUs) granted at no cash cost, increasing her direct holdings to 15,930 shares after the transaction.
The RSUs entitle her to one share of Common Stock for each unit when they vest. All 4,660 RSUs will vest on the earlier of June 10, 2027 or the next annual meeting following the grant date, as long as she continues to serve the company.
PACS Group, Inc. director Evelyn S. Dilsaver received a grant of 4,660 restricted stock units (RSUs) of Common Stock. The award was granted at no cash price per share as equity compensation.
Each RSU converts into one share upon vesting, and 100% of the RSUs will vest on the earlier of June 10, 2027 or the next annual meeting following the grant date, subject to her continued service. Following this grant, she directly holds 31,798 shares.
PACS Group, Inc. Chief Legal Officer & Secretary John Todd Mitchell sold 80,152 shares of common stock in open-market transactions. The sales occurred on May 15 and May 18, 2026 at weighted average prices in the high-$30 range under a pre-arranged Rule 10b5-1 trading plan adopted on December 8, 2025. Following these trades, he continues to hold more than 800,000 PACS shares directly.